Simon Couillard and Sanjay Ramakrishnan discuss their paths from medical school to becoming assistant professors in different parts of the world, the challenges they faced in securing academic positio...

Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, a cytokine that plays a central role in eosinophilic inflammation, which is present in 20 to 40% of patients with chronic ...

Blood eosinophil count, FeNO, asthma attack history, disease severity, low lung function (low FEV1%), and symptoms (ACQ-5 score) are key predictors of asthma attacks. Conversely, we found that moderat...

Introduction Chest computed tomography (CT) interpretation is a key competency for pulmonary fellows, with many resources intended for radiologists but very few for this specific group. We endeavored ...

This Review addresses the roles of type 2 immunity in cancer and the potential for cancer immunotherapies targeting this pathway.

This cross-sectional analysis uses data from 3 diverse studies to identify asthma endotypes in youths aged 6 to 20 years via the distribution and characteristics of transcriptomic profiles in nasal ep...

Background Recent breakthroughs in artificial intelligence research include the development of generative pretrained transformers (GPT). ChatGPT has been shown to perform well when answering several s...

Cases in domesticated cats have risen dramatically over the past year.

Study warns region’s exponential rise in incarceration is fuelling the disease, with cases increasing by 19% between 2015 and 2022

Nature Medicine asks leading researchers to name their top clinical trial for 2025, from gene therapies for prion disease and sickle-cell disease to digital tools for cancer and mental health.

Podcast Episode · Thorax Podcast · 12/18/2024 · 46m

Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. In these phase 3A, randomized, placebo-cont...

Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. In these phase 3A, randomized, placebo-cont...